The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with
multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline …

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

Abstract Background In 2012, the Food and Drug Administration approved use of
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …

Bedaquiline is a diarylquinoline antitubercular drug with a novel mechanism of action
against M ycobacterium tuberculosis. Bedaquiline works by inhibiting bacterial adenosine …

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial
limitations, in terms of their effectiveness, side-effect profile, and complexity of …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …

Improving treatment outcomes in multidrug‐resistant tuberculosis (MDR‐TB) is partly
hampered by inadequate effective antitubercular agents. Development of bedaquiline and …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …

In a cohort of 35 patients with multidrug-resistant and extensively drug-resistant tuberculosis,
individually tailored bedaquiline-containing regimens led to culture conversion in 97% of …